Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZ-801 Phase 3 in APOE4/4 Early Alzheimer's Disease
NL-OMON54459Phase 3Active, not recruiting
- Sponsor
- Alzheon, Inc.
- Start
- Mar 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing ALZ-801 with Placebo (2 arms). Primary endpoints: Change from baseline to Week 78 in ADAS-Cog 13, Change from baseline to Week 78 in CSF p-tau181 and 8 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON54459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54459.